This issue of BETA discusses sixteen possible antiviral treatments for HIV infection and includes an update on AZT studies. We have given special attention to AZT, dextran sulfate, Iscador, AL721, ribavirin, carrisyn and BHT because these substances are currently available to people considering antiviral treatments for HIV.
In the June 1988 issue of BETA we referred to the standard "full dose" of AZT as 200 mg every four hours (1200 mg every day). Recent studies, however, suggest that a half dose of AZT (600 mg every day) may be as effective . [56] In a study presented at Stockholm, researchers found that there was no difference in the antiviral effect of AZT at a half dose (200 mg every four hours).
Despite FDA approval for limited use, AZT is considered an experimental drug for HIV-infected individuals who show no symptoms of infection. Studies are now underway to determine the most effective dosage, long-term effects, how it works with other drugs and how beneficial it is at various stages of HIV infection.
A biweekly newsletter on experimental and alternative treatments for AIDS. To subscribe send $25 per quarter ($8 for people with AIDS or ARC) to John S. James, P.O. Box 411256, San Francisco, CA 94141, or call (415) 255-0588 anytime, 24 hours a day for information. Subscriptions include several back issues at no extra charge.
This information is designed to support, not replace, the relationship that exists between you and your doctor.